Aridis Pharmaceuticals Equity 2025

Aridis Pharmaceuticals Aktienanalyse

What does Aridis Pharmaceuticals do?

Aridis Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of immunotherapeutics and antibiotics for the treatment of infectious diseases. It was founded in 2003 in San Jose, California. The company's business model aims to address the gap in the infectious disease market caused by antibiotic resistance and the lack of new therapy options. Aridis has developed several patented technologies that allow for the quick and effective identification of potential candidates for new therapies. The company focuses on antibiotic development, utilizing a library of human monoclonal antibodies targeted specifically for infectious diseases. These antibodies can be used to target bacteria and achieve better efficacy against antibiotic resistance. Aridis has promising candidates in clinical development. The company also focuses on the development of immunotherapeutics for infectious diseases. They have developed a portfolio of monoclonal antibodies that target pathogenic microbes and can activate immune cells to strengthen the body's immune system. Some of Aridis' key products include Aerucin for the treatment of pneumonia and other respiratory diseases, and AR-101 for severe infections caused by Pseudomonas aeruginosa. Both products are currently in Phase II of development. Another important product is AR-301, a monoclonal antibody developed for the treatment of severe Staphylococcus infections. AR-301 has successfully completed Phase IIb studies and is currently undergoing accelerated approval by the US Food and Drug Administration (FDA). Aridis has formed collaborations with academic institutions and other biopharmaceutical companies to access the latest scientific knowledge and technologies. They have partnerships with multiple universities and research institutes worldwide. The company has also partnered with AmpliPhi Biosciences for the development of bacteriophage-based therapies for infectious diseases, and with Mount Sinai Health System for the development of immunotherapeutics for respiratory diseases. Overall, Aridis has a strong position in the infectious disease market and is well-positioned to address the gap caused by antibiotic resistance and the lack of new therapies. With a strong portfolio of patented technologies, promising candidates in clinical development, and broad partnerships, the company has the potential to become a leading player in the industry. Aridis Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Aridis Pharmaceuticals's Equity

Aridis Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Aridis Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Aridis Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Aridis Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Aridis Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Aridis Pharmaceuticals stock

What is the equity of Aridis Pharmaceuticals this year?

Aridis Pharmaceuticals has equity of -24.23 M USD this year.

What was the equity of Aridis Pharmaceuticals compared to the previous year?

The equity of Aridis Pharmaceuticals has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of Aridis Pharmaceuticals?

A high equity is advantageous for investors of Aridis Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Aridis Pharmaceuticals?

A low equity can be a risk for investors of Aridis Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Aridis Pharmaceuticals affect the company?

An increase in equity of Aridis Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Aridis Pharmaceuticals affect the company?

A reduction in equity of Aridis Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Aridis Pharmaceuticals?

Some factors that can affect the equity of Aridis Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Aridis Pharmaceuticals so important for investors?

The equity of Aridis Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Aridis Pharmaceuticals take to change the equity?

To change equity, Aridis Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Aridis Pharmaceuticals pay?

Over the past 12 months, Aridis Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aridis Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aridis Pharmaceuticals?

The current dividend yield of Aridis Pharmaceuticals is .

When does Aridis Pharmaceuticals pay dividends?

Aridis Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aridis Pharmaceuticals?

Aridis Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aridis Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aridis Pharmaceuticals located?

Aridis Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aridis Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aridis Pharmaceuticals from 7/28/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/28/2025.

When did Aridis Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/28/2025.

What was the dividend of Aridis Pharmaceuticals in the year 2024?

In the year 2024, Aridis Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aridis Pharmaceuticals pay out the dividend?

The dividends of Aridis Pharmaceuticals are distributed in USD.